Achilles Therapeutics Appoints Dr Edwin Moses as Chairman of its Board of Directors and Dr Iraj Ali as Chief Executive Officer
December 10, 2018 07:00 ET
|
Achilles Therapeutics
Achilles Therapeutics Appoints Dr Edwin Moses as Chairman of its Board of Directors and Dr Iraj Ali as Chief Executive Officer Stevenage, UK 10 December 2018 – Achilles Therapeutics (“Achilles” or...
Achilles Therapeutics Appoints Dr Edwin Moses as Chairman of its Board of Directors and Dr Iraj Ali as Chief Executive Officer
December 10, 2018 02:00 ET
|
Achilles Therapeutics
Achilles Therapeutics Appoints Dr Edwin Moses as Chairman of its Board of Directors and Dr Iraj Ali as Chief Executive Officer Stevenage, UK 10 December 2018 – Achilles Therapeutics (“Achilles” or...
Celsion Receives $11.1 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program
December 03, 2018 09:15 ET
|
Celsion CORP
Non-Dilutive Funding Strengthens Balance Sheet Proceeds Equate to More Than $0.55 Per Share LAWRENCEVILLE, N.J., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an...
Celsion Strengthens Its Balance Sheet with the Approval of Its Application to Sell Net Operating Losses for up to $10 Million in Non-Dilutive Funding
September 04, 2018 08:30 ET
|
Celsion CORP
Funding Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program LAWRENCEVILLE, N.J., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology...
Celsion Corporation Reports Second Quarter 2018 Financial Results and Provides Business Update
August 14, 2018 08:30 ET
|
Celsion CORP
Strong Balance Sheet With Cash Sufficient to Fund Operations Into the First Half of 2020 Quarterly and Year-to-Date Cash Expenses Consistent With Prior Guidance Company to Hold...
Galectin Therapeutics Granted Patents in China and Japan that Support NASH and Cancer Immunotherapy Clinical Development Programs
January 25, 2018 08:30 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat non-alcoholic steatohepatitis...
Immuron Commences US Non-Deal Institutional Investor Roadshow
August 15, 2017 09:15 ET
|
Immuron Limited
MELBOURNE, Australia, Aug. 15, 2017 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company Immuron Limited (ASX:IMC) (NASDAQ:IMRN) is pleased to release to shareholders and investors...
Combination Immunotherapy with Galectin-3 Inhibitor GR-MD-02 Enhances Effects in Pre-clinical Models and Early Results of Phase 1 Clinical Trials
February 07, 2017 16:40 ET
|
Galectin Therapeutics
NORCROSS, Ga., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, and the Providence Cancer Center today...